Poolbeg Pharma – a company concentrating on infectious diseases – has announced an update on its oral vaccine programme.
It follows the award of non-dilutive grant funding by the Irish government’s Disruptive Technologies Innovation Fund (DTIF) in November last year. This development was part of the Poolbeg-led ‘EncOVac Consortium’.
Subsequently, the research plan has been finalised and EncOVac Consortium parties are preparing to enter the next phase – to commence validation of the encapsulation process. Validation is expected to be completed later this year.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
